Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1994 Oct 15;309(6960):983–986. doi: 10.1136/bmj.309.6960.983

Glycated haemoglobin values: problems in assessing blood glucose control in diabetes mellitus.

E S Kilpatrick 1, A G Rumley 1, M H Dominiczak 1, M Small 1
PMCID: PMC2541274  PMID: 7950717

Abstract

OBJECTIVE--To see whether two measures of glycated haemoglobin concentration--the haemoglobin A1 (HbA1) value and the haemoglobin A1c (HbA1c) value--assess blood glucose control differently in diabetes. DESIGN--Diabetic patients had glycaemic control assessed on the basis of HbA1 and HbA1c values measured by the same high performance liquid chromatography instrument and on the basis of HbA1 measured by electrophoresis. SETTING--A diabetic outpatient clinic. SUBJECTS--208 diabetic patients and 106 non-diabetic controls. MAIN OUTCOME MEASURES--Glycated haemoglobin concentrations classified according to European guidelines as representing good, borderline, or poor glycaemic control by using standard deviations from a reference mean. RESULTS--Fewer patients were in good control (25;12%) and more poorly controlled (157;75%) as assessed by the HbA1c value compared with both HbA1 assays (39 (19%) and 130 (63%) respectively when using high performance liquid chromatography; 63 (30%) and 74 (36%) when using electrophoresis). The median patient value was 8.0 SD from the reference mean when using HbA1c, 5.9 when using HbA1 measured by the same high performance liquid chromatography method, and 4.1 when using HbA1 measured by electrophoresis. CONCLUSIONS--Large differences exist between HbA1 and HbA1c in the classification of glycaemic control in diabetic patients. The HbA1c value may suggest a patient is at a high risk of long term diabetic complications when the HbA1 value may not. Better standardisation of glycated haemoglobin measurements is advisable.

Full text

PDF
983

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberti K. G., Gries F. A. Management of non-insulin-dependent diabetes mellitus in Europe: a concensus view. Diabet Med. 1988 Apr;5(3):275–281. doi: 10.1111/j.1464-5491.1988.tb00984.x. [DOI] [PubMed] [Google Scholar]
  2. John W. G., Bullock D. G., MacKenzie F. Methods for the analysis of glycated haemoglobins: what is being measured? Diabet Med. 1992 Jan-Feb;9(1):15–19. doi: 10.1111/j.1464-5491.1992.tb01708.x. [DOI] [PubMed] [Google Scholar]
  3. Kilpatrick E. S., Small M., Rumley A., Dominiczak M. H. Increased fetal hemoglobin in insulin-treated diabetes mellitus contributes to the imprecision of glycohemoglobin measurements. Clin Chem. 1993 May;39(5):833–835. [PubMed] [Google Scholar]
  4. Page S. R., Peacock I. Blood glucose monitoring: does technology help? Diabet Med. 1993 Nov;10(9):793–801. doi: 10.1111/j.1464-5491.1993.tb00168.x. [DOI] [PubMed] [Google Scholar]
  5. Rumley A. G., Kilpatrick E. S., Dominiczak M. H., Small M. Evaluation of glycaemic control limits using the Ames DCA 2000 HbA1c analyser. Diabet Med. 1993 Dec;10(10):976–979. doi: 10.1111/j.1464-5491.1993.tb00016.x. [DOI] [PubMed] [Google Scholar]
  6. Wysocki T. Impact of blood glucose monitoring on diabetic control: obstacles and interventions. J Behav Med. 1989 Apr;12(2):183–205. doi: 10.1007/BF00846550. [DOI] [PubMed] [Google Scholar]
  7. Yatscoff R. W., Tevaarwerk G. J., Clarson C. L., Warnock L. M. Interference of fetal hemoglobin and labile glycosylated hemoglobin with measurements of glycosylated hemoglobin. Clin Chem. 1983 Mar;29(3):543–545. [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES